3.26
+0.12(+3.82%)
Currency In USD
| Previous Close | 3.14 |
| Open | 3.19 |
| Day High | 3.28 |
| Day Low | 3.09 |
| 52-Week High | 19.1 |
| 52-Week Low | 2.7 |
| Volume | 501,279 |
| Average Volume | 1.56M |
| Market Cap | 220.34M |
| PE | -2.45 |
| EPS | -1.33 |
| Moving Average 50 Days | 7.78 |
| Moving Average 200 Days | 12.16 |
| Change | 0.12 |
If you invested $1000 in Perspective Therapeutics, Inc. (CATX) 10 years ago, it would be worth $213.07 as of December 26, 2024 at a share price of $3.26. Whereas If you bought $1000 worth of Perspective Therapeutics, Inc. (CATX) shares 5 years ago, it would be worth $535.3 as of December 26, 2024 at a share price of $3.26.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Perspective Therapeutics to Participate in Upcoming Investor Conferences in December
GlobeNewswire Inc.
Nov 27, 2024 12:00 PM GMT
SEATTLE, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, tod
Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium
GlobeNewswire Inc.
Nov 21, 2024 12:15 PM GMT
[212Pb]VMT-α-NET continued to have a favorable safety profile, with no dose-limiting toxicities observed at the two doses tested (2.5 and 5.0 mCi)Eight of nine patients had durable control of disease. Six of nine patients had a measurable reduction o
Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024
GlobeNewswire Inc.
Nov 15, 2024 9:08 PM GMT
SEATTLE, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, tod